Praha, Czechia

Sindelar Karel


Average Co-Inventor Count = 11.0

ph-index = 3

Forward Citations = 72(Granted Patents)


Location History:

  • Prague, CZ (1999)
  • Praha, CZ (2000)

Company Filing History:


Years Active: 1999-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Sindelar Karel: Innovator in Azaheterocyclic Compounds

Introduction

Sindelar Karel is a notable inventor based in Praha, Czech Republic. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds for clinical applications. With a total of 3 patents, Karel's work focuses on addressing painful and inflammatory conditions through innovative chemical solutions.

Latest Patents

Karel's latest patents include groundbreaking inventions such as N-substituted azaheterocyclic carboxylic acids and esters thereof. This invention relates to novel compounds that incorporate a substituted alkyl chain as part of the N-substituent. These compounds are designed for clinical treatment of painful, hyperalgesic, and inflammatory conditions where C-fibers play a crucial role in eliciting neurogenic pain or inflammation. Another significant patent involves substituted dibenz[b,f]azepines, which also aim to provide therapeutic solutions for similar medical conditions.

Career Highlights

Throughout his career, Karel has worked with prominent companies in the pharmaceutical industry, including Novo Nordisk A/S. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Karel has collaborated with esteemed colleagues such as Knud Erik Andersen and Rolf Hohlweg. These partnerships have fostered a collaborative environment that enhances the development of new inventions and research.

Conclusion

Sindelar Karel's contributions to the field of chemistry and his innovative patents demonstrate his commitment to improving clinical treatments for painful conditions. His work continues to influence the pharmaceutical industry and offers hope for better therapeutic options in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…